Emerging adenoviral vectors for stable correction of genetic disorders

Current Gene Therapy

Volumn 7, Issue 4, 2007, Pages 272-283

  Jager, Lorenz ^a   Ehrhardt, Anja ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adenovirus; Episomal persistence; Genetic disease; Hybrid vector; Persistence; Serotype; Sitespecific; Somatic integration

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; BETACELLULIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; NEUROGENIC DIFFERENTIATION FACTOR; NEURON SPECIFIC ENOLASE; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; VIRUS DNA;

ASPARTYLGLYCOSAMINURIA; CELL DIVISION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DIABETES MELLITUS; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; EPISOME; GENE EXPRESSION; GENE TRANSFER; GENETIC DISORDER; GENETIC TRANSDUCTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERCHOLESTEROLEMIA; MAMMAL CELL; NONHUMAN; REVIEW; SEROTYPE; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRUSES, HUMAN; ANIMALS; DEPENDOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC DISEASES, INBORN; GENETIC VECTORS; GENOME, VIRAL; HUMANS; PLASMIDS; RECOMBINATION, GENETIC; SEROTYPING; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

EID: 34547732865     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652307781369074     Document Type: Review

References (118)

1. Abroi, A., Ilves, I., Kivi, S., and Ustav, M. (2004) Analysis of chromatin attachment and partitioning functions of bovine papillomavirus type 1 E2 protein. J. Virol., 78: 2100-13.
2. Angeletti, P. C., and Engler, J. A. (1998) Adenovirus preterminal protein binds to the CAD enzyme at active sites of viral DNA replication on the nuclear matrix. J. Virol. 72: 2896-904.
3. Bangari, D. S., Shukla, S., and Mittal, S.K. (2005) Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem. Biophys. Res. Commun., 327: 960-6.
4. Barr, D., Tubb, J., Ferguson, D., Scaria, A., Lieber, A., Wilson, C., Perkins, J., and Kay, M.A. (1995) Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther., 2: 151-5.
5. Bauer, U., Flunker, G., Bruss, K., Kallwellis, K., Liebermann, H., Luettich, T., Motz, M., and Seidel, W. (2005) Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J. Clin. Microbiol., 43: 4426-33.
6. Brouwer, E., Havenga, M.J., Ophorst, O., De Leeuw, B., Gijsbers, L., Gillissen, G., Hoeben, R.C., Ter Horst, M., Nanda, D., Dirven, C., Avezaat, C.J., Goudsmit, J., and Sillevis Smitt, P. (2007) Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther., 14: 211-9.
7. Brown, B. D., Shi, C.X., Rawle, F.E., Tinlin, S., Mckinven, A., Hough, C., Grahem, F.L., and Lillicrap, D. (2004) Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J. Thromb. Haemost., 2: 111-8.
8. Brunetti-Pierri, N., Ng, T., Iannitti, D.A., Palmer, D.J., Beaudet, A.L., Fine-gold, M.J., Carey, K.D., Cioffi, W.G., and Ng, P. (2006) Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum. Gene Ther., 17: 391-404.
9. Brunetti-Pierri, N., Stapleton, G.E., Palmer, D.J., Zuo, Y., Mane, V.P., Finegold, M.J., Beaudet, A.L., Leland, M.M., Mullins, C.E., and Ng, P. (2007) Pseudo-hydrodynamic Delivery of Helper-dependent Adenoviral Vectors into Non-human Primates for Liver-directed Gene Ther., 15: 732-40.
10. Buchholz, C. J., and K. Cichutek (2006) Is it going to be SIN? a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold. J. Gene Med., 8: 1274-6.
11. Buning, H., Braun-Falco, M. and Hallek, M. (2004) Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs. 177(3):139-50. Review.
12. Chalberg, T. W., Portlock, J.L., Olivares, E.C., Thyagarajan, B., Kirby, P.J., Hillman, R.T., Hoelters, J., and Calos, M.P. (2006) Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol., 357: 28-48.
13. Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R., and Wilson, J. (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther., 6: 1574-83.
14. Clemens, P. R., Kochanek, S., Sunada, Y., Chan, S., Chen, H.H., Campbell, K.P., and Caskey, C.T. (1996) In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther., 3: 965-72.
15. Crettaz, J., Berraondo, P., Mauleon, I., Ochoa, L., Shankar, V., Barajas, M., Van Rooijen, N., Kochanek, S., Qian, C., Prieto, J., Hernandez-Alcoceba, R., and Gonzalez-Aseguinolaza, G. (2006.) Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology, 44: 623-32.
16. DiPaolo N, Ni S, Gaggar A, Strauss R, Tuve S, Li ZY, Stone D, Shayakhmetov D, Kiviat N, Toure P, Sow S, Horvat B, Lieber A. (2006) Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther., 13(4):756-65.
17. Dudley, R. W., Lu, Y., Gilbert, R., Matecki, S., Nalbantoglu, J., Petrof, B.J., and Karpati, G. (2004) Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum. Gene Ther., 15: 145-56.
18. Ehrhardt, A., Engler, J.A., Xu, H., Cherry, A.M., and Kay, M.A. (2006) Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum. Gene Ther., 17: 1077-94.
19. Ehrhardt, A. and M. A. Kay (2002) A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood, 99: 3923-30.
20. Ehrhardt, A., Xu, H., Dillow, A.M., Bellinger, D.A., Nichols, T.C., and Kay, M.A. (2003a) A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood, 102: 2403-11.
21. Ehrhardt, A., Xu, H., and Kay, M.A. (2003b) Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J. Virol., 77: 7689-95.
22. Ehrhardt, A., Yant, S.R., Giering, J.C., Xu, H., Engler, J.A., and Kay, M.A. (2007) Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol. Ther., 15: 146-56.
23. Farina, S.F., Gao, G.P., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., Marsh, J., Ertl, H.C., and Wilson, J.M. (2001) Replication-defective vector based on a chimpanzee adenovirus. J. Virol., 75: 11603-13.
24. Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., Schoemaker, R., Veghel, R., Houtsmuller, A., Schultheiss, H.P., Lamers, J., and Poller, W. (1999) Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther., 6: 1520-35.
25. Fredman, J. N., and Engler, J. A. (1993) Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J. Virol., 67: 3384-95.
26. Gaggar, A., Shayakhmetov, D.M., and Lieber, A. (2003) CD46 is a cellular receptor for group B adenoviruses. Nat. Med., 9: 1408-12.
27. Gall, J., Kass-Eisler, A., Leinwand, L., and Falck-Pedersen, E. (1996) Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol., 70: 2116-23.
28. Ghosh, SS, Gopinath, P and Ramesh, A (2006) Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol., 133(1):9-29. Review.
29. Gilbert, R., Dudley, R.W., Liu, A.B., Petrof, B.J., Nalbantoglu, J., and Karpati, G. (2003) Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum. Mol. Genet., 12: 1287-99.
30. Gilbert, R., Nalbantoglu, J., Petrof, B.J., Ebihara, S., Guibinga, G.H., Tinsley, J.M., Kamen, A., Massie, B., Davies, K.E., and Karpati, G. (1999) Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther., 10: 1299-310.
31. Ginsburg, D. S., and Calos M. P. (2005) Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv. Genet., 54: 179-87.
32. Goncalves MA, van Nierop GP, Tijssen MR, Lefesvre P, Knaan-Shanzer S, van der Velde I, van Bekkum DW, Valerio D, de Vries AA. (2005) Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J. Virol., 79(5):3146-62.
33. Goncalves, M. A., Holkers, M., Cudre-Mauroux, C., Van Nierop, G.P., Knaan-Shanzer, S., Van Der Velde, I., Valerio, D., and De Vries, A.A. (2006) Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Mol. Ther., 13: 976-86.
34. Grubb, B.R., Pickles, R.J., Ye, H., Yankaskas, J.R., Vick, R.N., Engelhardt, J.F., Wilson, J.M., Johnson, L.G., and Boucher, R.C. (1994) Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature, 371: 802-806.
35. Hacein-Bey-Abina, Von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., Mcintyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calva, M., and Fischer, A. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348: 255-6.
36. Harvey, B. G., Hackett, N.R., El-Sawy, T., Rosengart, T.K., Hirschowitz, E.A., Liebermann, M.D., Lesser, M.L., and Crystal, R.G. (1999) Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol., 73: 6729-42.
37. Havenga, M.J., Lemckerk, A.A., Grimbergen, J.M., Vogels, R., Huisman, L.G., Valero, D., Bout, A., and Quax, P.H. (2001) Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol., 75: 3335-3342.
38. Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. (2002) Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol., 76: 4612-20.
39. Hillgenberg, M., Tonnies, H., Strauss, M. (2001) Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J. Virol., 75: 9896-908.
40. Ho, A. Y., Adams, S., Shaikh, H., Pagliuca, A., Devereux, S., and Mufti, G.J. (2002) Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant., 29: 867-9.
41. Jaffe, H.A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M.A, Gant, T.W., Thorgeirsson, S.S., Stratford-Perricaudet, L.D., Perricaudet, M., Pavirani, A., Lecocq, J.-P., and CrystaL R.G. (1992) Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet., 1: 372-78.
42. Jenke, A. C., Stehle, I.M., Herrman, F., Eisenberger, Y., Baiker, A., Bode, J., Fackelmayer, F.O., and Lipps, H.J. (2004) Nuclear scaffold/ matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl. Acad Sci. USA, 101: 11322-7.
43. Kass-Eisler, A., Leinwand, L., Gall, J., Bloom, B., and Falck-Pedersen, E. (1996) Circumventing the immune response to adenovirus-mediated gene therapy." Gene Ther., 3: 154-62.
44. Kay, M.A., Lander, C.N., Rothenberg, S.R., Taylor, L.A., Leland, F., Wiehle, S., Fang, B., Bellenger, D., Finegold, M., Thompson, A.R., Read, M.S., Brinkhous, K.M., Woo, S.L.C. (1994) In vivo hepatic gene therapy: Complete albeit transient correction of Factor IX deficiency in Hemophilia B dogs. Proc. Natl. Acad. Sci. U S A, 91:2353-57.
45. Keriel, A., Rene, C., Galer, C., Zabner, J., and Kremer, E.J. (2006) Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J. Virol., 80: 1487-96.
46. Kim, I. H., Jozkowicz, A., Piedra, P.A., Oka, K., and Chan, L. (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. U S A, 98: 13282-7.
47. Knaan-Shanzer S, Van Der Velde I, Havenga MJ, Lemckert AA, De Vries AA, Valerio D. (2002) Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum Gene Ther. 1; 12(16):1989-2005. Erratum in: Hum Gene Ther., 2003 Aug 10:14(12):1214.
48. Koehler, D. R., Martin, B., Corey, M., Palmer, D., Ng, P., Tanswell, A.K., and Hu, J. (2006) Readministration of helper-dependent adenovirus to mouse lung. Gene Ther., 13: 773-80.
49. Kojima, H., Fuyimiya, M., Matsumara, K., Younan, P., Imaeda, H., Maeda, M., and Chan, L. (2003) NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat. Med., 9: 596-603.
50. Krasnykh, V. N., Mikheeva, G. V., Douglas, J.T., and Curiel, D.T. (1996) Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol., 70: 6839-6846.
51. Kubo, S., Seleme Mdel, C., Soifer, H.S., Perez, J.L., Moran, J.V., Kazazian, H.H., JR., and Kasahara, N. (2006) L1 retrotransposition in nondividing and primary human somatic cells. Proc. Natl. Acad. Sci. U S A, 103: 8036-41.
52. Lecollinet, S., Gavard, F., Havenga, M.J., Spiller, O.B., Lemckert, A., Goudsmit, J., Eloit, M., and Richardson, J. (2006) Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. J. Virol., 80: 2747-2759.
53. Lewinski, M.K. and Bushman, F.D. (2005) Retroviral DNA integration-mechanism and consequences. Adv. Genet., 55: 147-81
54. Lieber, A., He, C.Y., and Kay, M.A. (1997) Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat. Biotechnol., 15: 1383-7.
55. Liu, J., Jeppesen, I., Nielsen, K., and Jensen, T.G. (2006) Phi c31 integrase induces chromosomal aberrations in primary human fibroblasts. Gene Ther., 13: 1188-90.
56. Loewen, N and Poeschla, EM (2005) Lentiviral vectors. Adv. Biochem. Eng. Biotechnol., 99: 169-91. Review.
57. Lusky, M., Christ, M., Rittner, K., Dieterle, A., Dreyer, D., Mourot, B., Schultz, H., Stoeckel, F., Pavirani, A., and Mehtali, M. (1998) In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol., 72: 2022-32.
58. Mane, V. P., Toietta, G., McCormack, W.M., Conde, I., Clarke, C., Palmer, D., Finegold, M.J., Pastore, L., Ng, P., Lopez, J., and Le, B. (2006) Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther., 13: 1272-80.
59. Manno, C. S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., and Kay, M.A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12: 342-7.
60. McCormack, W. M., Jr., Seiler, M.P., Bertin, T.K., Ubhayakar, K., Palmer, D.J., Ng, P., Nichols, T.C., and Le, B. (2006) Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J. Thromb. Haemost., 4: 1218-25.
61. Mian, A., McCormack, W.M., Jr., Mane, V., Kleppe, S., Ng, P., Finegold, M., O'Brien, W.E., Rodgers, J.R., Beaudet, A.L., and Lee, B. (2004) Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol. Ther., 10: 492-9.
62. Miller, D.G., Petek, L.M., and Russell, D.W. (2004) Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet., 36: 767-73.
63. Mitani, K. and S. Kubo, S. (2002) Adenovinis as an integrating vector. Curr. Gene Ther., 2: 135-44.
64. Mizuguchi, H. and Hayakawa, T. (2002) Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene, 285: 69-77.
65. Moffatt, S., Hays, J., Hogenesch, H., and Mittal, S.K. (2000) Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology, 272: 159-67.
66. Morral, N., O'Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P.A., Zhou, H., Parks, R.J., Velji, R., Aguilar-Cordova, E., Wadsworth, S., Graham, F.L., Kochanek, S., Carey, K.D., and Beaudet, A.L. (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U S A, 96: 12816-21.
67. Murphy, S.J., Chong, H., Bell, S., Diaz, R.M., and Vile, R.G. (2002) Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum. Gene Ther., 13: 745-60.
68. Nakai, H., Montini, E., Fuess, S., Storm, T.A., Grompe, M., and Kay, M.A. (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet., 34: 297-302.
69. Nakai, H., Yant, S.R., Storm, T.A., Fuess, S., Meuse, L., and Kay, M.A. (2001) Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol., 75: 6969-76.
70. Nelson, J. E., and Kay, M.A. (1997) Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J. Virol., 71: 8902-7.
71. Ohbayashi, F., Balamotis, M. A., Kishimoto, A., Aizawa, E., Diaz, A., Hasty, P., Graham, F. L., Caskey, C. T., Mitani, K. (2005) Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors. Proc. Natl. Acad. Sci. U S A, 102: 13628-33.
72. Palmer, D., and Ng, P. (2003) Improved system for helper-dependent adenoviral vector production. Mol. Ther., 8: 846-52.
73. Parks, R. J., Bramson, J.L., Wan, Y., Addison, C.L., and Graham, F.L. (1999) Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J. Virol., 73: 8027-34.
74. Picard-Maureau, M., Kreppel, F., Lindemann, D., Juretzek, T., Herchenroder, O., Rethwilm, A., Kochanek, S., and Heinkelein, M. (2004) Foamy virus-adenovirus hybrid vectors. Gene Ther., 11: 722-8.
75. Piechaczek, C., Fetzer, C., Baiker, A., Bode, J., and Lipps, H.J. (1999) A vector based on the SV40 origin of replication and chromosomal S/MARs ŕeplicates episomally in CHO cells. Nucleic Acids Res., 27: 426-8.
76. Plog, M. S., Guyre, C.A., Roberts, B.L., Goldberg, M., St George, J.A., and Perricone, M.A. (2006) Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Hum. Gene Ther., 17: 705-16.
77. Raper, S. E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80: 148-58.
78. Recchia, A., Perani, L., Sartori, D., Olgiati, C., and Mavilio, F. (2004) Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther., 10: 660-70.
79. Reddy, P. S., Idamakanti, N., Hyun, B.H., Tikoo, S.K., and Babiuk, L.A. (1999) Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol., 80: 563-70.
80. Reddy, P. S., Sakhuja, K., Ganesh, S., Yang, L., Kayda, D., Brann, T., Pattison, S., Golightly, D., Idamakanti, N., Pinkstaff, A., Kaloss, M., Barjot C., Chamberlain, J.S., Kaleko, M., and Connelly, S. (2002) Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol. Ther., 5: 63-73.
81. Roberts, D.M., Nanda A., Havenga, M.J. E., Abbink, P., Lynch D.M., Ewald, B.A., Liu, J., Thomer, A.R., Swanson, P.E., Gorgone, D.M., Lifton, M.A., Lemckert, A.A.C., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K.G., Goudsmit J., and Barouch D.H. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting anti-vector immunity. Nature, 441, 239-43.
82. Romano, G. (2006) The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand? Drug News Perspect., 19(2):99-106. Review.
83. Roy, S., Shirley, P.S., McLelland, A., and Kaleko, M. (1998) Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol., 72: 6875-9.
84. Ruzsics, Z., Wagner, M., Osterlehner, A., Cook, J., Koszinowski, U., and Burgert, H.G. (2006) Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D. J. Virol., 80: 8100-13.
85. Sandig, V., Youil, R., Bett, A.J., Franlin, L.L., Oshima, M., Maione, D., Wang, F., Metzker, M.L., Savino, R., and Caskey, C.T. (2000) Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. U S A, 97: 1002-7.
86. + cells by an adenovirus type 35 vector. Gene Ther., 10: 1041-48.
87. Schiedner, G., Morral, N., Parks, R.J., Wu, Y., Koopmans, S.C., Langston, C., Graham, F.L., Beaudet, A.L., and Kochanek, S. (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet., 18: 180-3.
88. Schmitz, H., Wigand, R., and Heinrich, W. (1983) Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol., 117: 455-66.
89. Schowalter, D. B., Himeda, C.L., Winther, B.L., Wison, C.B., and Kay, M.A. (1999) Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice. J. Virol., 73: 4755-66.
90. Sclimenti, C. R., and Calos M. P. (1998) Epstein-Barr virus vectors for gene expression and transfer. Curr. Opin. Biotechnol., 9: 476-9.
91. Segerman, A., Atkinson, J.P., Marttila, M., Dennerquist, V., Wadell, G., Arnberg, N. (2003) Adenovirus scrotype 11 uses CD46 as a cellular receptor. J. Virol., 77: 9183-91.
92. Shapiro, G. S., Van Peursem, C., Ornelles, D.A., Schaak, J., and Degregori, J. (2006) Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 protein. J. Virol., 80: 5349-60.
93. Shayakhmetov, D.M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000). Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol., 74, 2567-83.
94. Shayakhmetov, D.M., Carlson, C.A., Stecher, H., LI, Q., Stamatoyannopoulos, G., and Lieber, A. (2002). A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J. Virol., 76, 1135-1143.
95. Snyder, R. O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winthet, B., Meuse, L., Cohen, L.K., Thompson, A.R., and Kay, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet., 16(3): 270-6.
96. Soifer, H., Higo, C., Logg, C.R., Jib, L.J., Shichinohe, T., Harboe-Schmidt, E., Mitani, K., and Kasahara, N. (2002) A novel, helper-dependent, adenovirus-retrovizus hybrid vector: stable transduction by a two-stage mechanism. Mol. Ther., 5: 599-608.
97. Song, S., Lu, Y., Choi, Y.K., Han, Y., Tang, Q., Zhao, G., Berns, K.I., and Flotte, T.R. (2004). DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc. Natl. Acad. Sci U S A, 101: 2112-6.
98. Stecher H, Shayakhmetov DM, Stamatoyannopoulos G, Lieber A. (2001) A capsid-modified adenovirus vector devoid of all vital genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. 4(1):36-44.
99. Stevenson, S.C., Rollence, M., and Marshall-Neff, J. (1997) Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol., 71: 4782-4790.
100. Swazo, N. K. (2006) Calculating risk/benefit in X-linked severe combined immune deficiency disorder (X-SCID) gene therapy trials: the task of ethical evaluation. J. Med. Philos., 31: 533-64.
101. Tan, B. T., Wu, L., and Berk, A.J. (1999) An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J. Virol., 73: 7582-9.
102. Tatsis, N., Blejer, A., Lasaro, M.O., Hensley, S.E., Cun, A., Tesema, L., Li, Y., Gao, G.P., Xiang, Z.Q., Zhou, D., Wilson, J.M., and Ertl, H.C. (2007) A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier. Mol. Ther., 15: 608-17.
103. Toietta, G., Koehler, D.R., Finegold, M.J., Lee, B., Hu; J., and Beaudet, A.L. (2003) Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol. Ther., 7: 649-58.
104. Varnavski, A. N., Calcedo, R., Bove, M., Gao, G., and Wilson, J.M. (2005) Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector in vector-naive and pre-immunized mice. Gene Ther., 12: 427-36.
105. Virta, S., Rapola, J., Jalanko, A., and Laine, M. (2006) Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse. J. Gene Med., 8: 699-706.
106. Vogels, R., Zuijdgeest, D., Van Rijnsoever, R., Hartkoom, E., Damen, I., De Bethune, M.P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., Cecchini, M., Wetterwald, A., Sprangers, M., Lemckert, A., Ophorst, O., Koel, B., Van Meerendonk, M., Quax, P., Panitti L., Grinbergen, J., Bout, A., Goudsmit, J., and Havenga, M. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol., 77: 8263-71.
107. Voitenleitner, C., and Botchan, M. (2002) E1 protein of bovine papillomavirus type 1 interferes with E2 protein-mediated tethering of the viral DNA to mitotic chromosomes. J. Virol., 76: 3440-51.
108. Wadsworth, S. C., Zhou, H., Smith, A.E., and Kaplan, J.M. (1997) Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol., 71: 5189-96.
109. Wang, H., and Lieber (2006) A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette. J. Virol., 80: 11699-709.
110. Wu, S. C., Meir, Y.J., Coates, C.J., Handler, A.M., Pelczar, P., Moisyadi, S., and Kaminski, J.M. (2006) piggyBac is a flexible and highly active transposon as compared to sleeping beauty, To12, and Mos1 in mammalian cells. Proc. Natl. Acad. Sci U S A, 103: 15008-13.
111. Yant, S. R., Ehrhardt, A., Mikkelsen, J.G., Meuse, L., Pham, T., and Kay, M.A. (2002) Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol., 20: 999-1005.
112. Yant, S. R., Huang, Y., Akache, B., and Kay, M.A. (2007) Site-directed transposon integration in human cells. Nucleic Acids Res., [Epub ahead of print]
113. Yant, S. R., Park, J., Huang, Y., Mikkelsen, J.G., and Kay, M.A. (2004) Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol. Cell. Biol., 24: 9239-47.
114. Yant, S. R., Wu, X., Huang, Y., Garrison, B., Burgess, S.M., and Kay, M.A. (2005) High-resolution genome-wide mapping of transposon integration in mammals. Mol. Cell. Biol., 25: 2085-94.
115. Ye, X., Robinson, M.B., Pabin, C., Quinn, T., Jawad, A., Wilson, J.M., and Batshaw, M.L. (1997) Adenovirus-mediated in vivo gene transfer rapidly protects omithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr. Res., 41: 527-34.
116. Zabner, J., Petersen, D.M., Puga, A.P., Graham, S.M., Couture, L.A., Keyes, L.D., Lukason, M.J., St. George, J.A., Gregory, R.J., Smith, A.E., and Welsh, M.J. (1994) Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet., 6: 75-83.
117. Zabner, J., Chillon, M., Grunst, T., Moninger, T.O., Davidson, B.L., Gregory, R., and Armentano, D. (1999) A Chimeric Type 2 Adenovirus Vector with a Type 17 Fiber Enhances Gene Transfer to Human Airway Epithelia. J Virol., 73: 8689-95.
118. Zheng, C., Baum, B.J., Iadarola, M.J., and O'Connell, B.C. (2000) Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol., 18: 176-80.